Dr. Somnath Chatterjee has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Somnath Chatterjee, on behalf of the promoters, promoter group, and persons acting in concert of Suraksha Diagnostic Limited, has submitted a declaration to BSE and NSE confirming compliance with Regulation 31(4) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. The declaration states that no new encumbrance (such as pledge or lien) has been created on shares held by the promoters in Suraksha Diagnostic Limited during the financial year ended March 31, 2025, beyond what was already disclosed. The filing includes an extensive annexure listing all promoter group individuals (across the Chatterjee, Mittal, and Verma families) and 62 promoter group entities, including several 'Terrific' series LLPs and other investment and real estate companies.
This is a routine annual compliance filing and is neutral to mildly positive for shareholders. It confirms that promoters have not pledged or encumbered additional shares, signalling continued confidence in the company and no immediate margin pressure on promoter holdings.